{"id":60487,"date":"2024-02-28T06:51:06","date_gmt":"2024-02-28T06:51:06","guid":{"rendered":"https:\/\/medsname.com\/rofaday\/"},"modified":"2026-04-30T10:23:46","modified_gmt":"2026-04-30T10:23:46","slug":"rofaday","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/rofaday\/","title":{"rendered":"Rofaday"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 28px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 10px 0;font-size:18px;color:#1a1a1a;\">\u26a1 Quick Answer \u2014 What is Rofaday?<\/h3>\n<p><strong>Rofaday<\/strong> inneh\u00e5ller <strong>roflumilast 500 mcg<\/strong>, en <strong>oral selective phosphodiesterase-4 (PDE4) inhibitor<\/strong> taken once daily for <strong>severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis phenotype and frequent exacerbations<\/strong>. Roflumilast is anti-inflammatory rather than bronchodilator \u2014 it suppresses neutrophil and macrophage activation in airways, reducing exacerbation frequency by ~17% in landmark trials (M2-124, M2-125, REACT). It is added on top of optimal LAMA + LABA (\u00b1 ICS) in patients with severe disease. Manufactured by <strong>Cipla<\/strong>.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Vad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade <a href=\"https:\/\/medsbase.com\/sv\/reviews\/\">kundrecensioner<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r <a href=\"https:\/\/medsbase.com\/sv\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n<h3>Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n<p>V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #e0e0e0;padding:12px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;text-align:center;\">\n<strong>\ud83d\udd12 Krypterad kassaprocess<\/strong> \u00b7 <strong>\ud83d\udcb3 Verifierad betalningsprocessor<\/strong> \u00b7 <strong>\ud83d\ude9a V\u00e4rldsomsp\u00e4nnande leverans<\/strong> \u00b7 <strong>\u2b50 4.9\/5 av 1 400+ kunder<\/strong>\n<\/div>\n<h2>What Is Rofaday?<\/h2>\n<p>Rofaday is an oral PDE4 inhibitor for severe COPD. Roflumilast is the only PDE4 inhibitor licensed for COPD \u2014 sold internationally as Daxas (AstraZeneca) and Daliresp. It is a niche but well-evidenced add-on for the chronic bronchitis phenotype.<\/p>\n<h2>How Does Rofaday Work?<\/h2>\n<p>Phosphodiesterase-4 (PDE4) is the dominant cyclic AMP-degrading enzyme in inflammatory cells (neutrophils, macrophages, eosinophils, T-cells). Inhibiting PDE4 raises cyclic AMP in these cells, suppressing:<\/p>\n<ul>\n<li>Neutrophil chemotaxis and degranulation in airways<\/li>\n<li>Macrophage cytokine release (TNF-\u03b1, IL-8)<\/li>\n<li>Airway smooth-muscle proliferation and fibroblast activation<\/li>\n<li>Mucus hypersecretion and goblet-cell hyperplasia<\/li>\n<\/ul>\n<p>The clinical result is a 15\u201317% reduction in COPD exacerbation rate when added to optimal inhaled therapy.<\/p>\n<h2>Anv\u00e4ndningsomr\u00e5den och indikationer<\/h2>\n<ul>\n<li><strong>Severe COPD (FEV1 &lt;50% predicted) with chronic bronchitis<\/strong> and a history of exacerbations, on top of optimal LAMA + LABA (\u00b1 ICS)<\/li>\n<li><strong>Frequent exacerbator phenotype<\/strong> with persistent productive cough<\/li>\n<\/ul>\n<h2>Rofaday Dosage<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Patient<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Dos<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Frekvens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Adults \u2014 start<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>250 mcg<\/strong> for first 4 weeks<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">En g\u00e5ng dagligen<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Vuxna \u2014 underh\u00e5ll<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>500 mcg<\/strong><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Once daily, with or without food<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Leverp\u00e5verkan<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid (Child-Pugh B\/C)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Side Effects of Rofaday<\/h2>\n<ul>\n<li><strong>Viktnedg\u00e5ng<\/strong> (averages 2\u20133 kg in trials \u2014 monitor; reverse if &gt;5%)<\/li>\n<li>Diarrhoea, nausea (commonest reason for discontinuation; usually settles after first 2\u20134 weeks)<\/li>\n<li>Huvudv\u00e4rk<\/li>\n<li>S\u00f6mnl\u00f6shet, \u00e5ngest<\/li>\n<li>Dyspepsia, abdominal pain<\/li>\n<li>Mood changes \u2014 depression, anxiety; rarely suicidal ideation (warning)<\/li>\n<\/ul>\n<p><strong>Allvarligt \u2014 avbryt och s\u00f6k hj\u00e4lp:<\/strong><\/p>\n<ul>\n<li>Severe weight loss (&gt;5% body weight)<\/li>\n<li>New or worsening depression, suicidal thoughts<\/li>\n<li>Severe persistent diarrhoea<\/li>\n<li>Allvarlig allergisk reaktion<\/li>\n<\/ul>\n<h2>Varningar och f\u00f6rsiktighets\u00e5tg\u00e4rder<\/h2>\n<ul>\n<li><strong>Mood and behaviour:<\/strong> screen for depression before starting; warn patients\/families to report new mood symptoms.<\/li>\n<li><strong>Weight loss:<\/strong> baseline and 3-monthly weight monitoring; if loss exceeds 5%, review or stop.<\/li>\n<li><strong>Nedsatt leverfunktion:<\/strong> avoid in Child-Pugh B and C.<\/li>\n<li><strong>4-week dose titration<\/strong> (250 mcg) reduces GI side effects and diarrhoea \u2014 most patients can then tolerate 500 mcg.<\/li>\n<li><strong>Not a bronchodilator<\/strong> \u2014 does not replace LAMA, LABA, or ICS.<\/li>\n<li><strong>Graviditet och amning:<\/strong> Kontraindikerat.<\/li>\n<li><strong>L\u00e4kemedelsinteraktioner:<\/strong> CYP3A4 inducers (rifampicin) reduce levels \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/li>\n<\/ul>\n<h2>Kontraindikationer<\/h2>\n<ul>\n<li>Hypersensitivity to roflumilast<\/li>\n<li>Moderate-to-severe hepatic impairment (Child-Pugh B\/C)<\/li>\n<li>Graviditet<\/li>\n<\/ul>\n<h2>L\u00e4kemedelsinteraktioner<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Interagerande l\u00e4kemedel<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Effekt<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Vad man ska g\u00f6ra<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">CYP3A4 inducers (rifampicin, phenobarbital, phenytoin, carbamazepine)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce roflumilast levels by 50%<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Undvik<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise roflumilast levels \u2014 increase side effect risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Caution; consider lower dose<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Oral contraceptives containing gestodene<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Modest increase in roflumilast levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No dose adjustment usually needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>F\u00f6rvaring<\/h2>\n<ul>\n<li>F\u00f6rvara under <strong>25\u00b0C<\/strong> p\u00e5 en sval, torr plats skyddad fr\u00e5n direkt solljus.<\/li>\n<li>F\u00f6rvara i originalf\u00f6rpackning tills anv\u00e4ndning f\u00f6r att skydda mot fukt och ljus.<\/li>\n<li>Anv\u00e4nd inte efter utg\u00e5ngsdatumet som st\u00e5r p\u00e5 f\u00f6rpackningen.<\/li>\n<li>H\u00e5ll utom r\u00e4ckh\u00e5ll f\u00f6r barn.<\/li>\n<\/ul>\n<h2>Relaterade alternativ p\u00e5 MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/sv\/asthalin-inhaler\/\"><strong>Asthalin Inhalator \u2014 salbutamol lindrande<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/budecort-inhaler\/\"><strong>Budecort Inhalator \u2014 budesonide ICS f\u00f6rebyggande<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/foracort-inhaler\/\"><strong>Foracort Inhalator \u2014 budesonide + formoterol ICS-LABA<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/tiova-inhaler\/\"><strong>Tiova Inhalator \u2014 tiotropium LAMA f\u00f6r KOL<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/montair\/\"><strong>Montair \u2014 montelukast LTRA-tablett<\/strong><\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">Vanliga fr\u00e5gor<\/h2>\n<h3>When is Rofaday added?<\/h3>\n<p>For severe COPD (FEV1 <50% predicted) with chronic bronchitis phenotype and a history of frequent exacerbations on top of optimal LAMA + LABA (\u00b1 ICS). Not for mild COPD or asthma.<\/p>\n<h3>Why must I start at 250 mcg?<\/h3>\n<p>A 4-week titration at 250 mcg dramatically reduces GI side effects (diarrhoea, nausea) \u2014 most patients can then move to the maintenance 500 mcg without intolerance.<\/p>\n<h3>How much does Rofaday reduce exacerbations?<\/h3>\n<p>About 15\u201317% reduction in moderate-to-severe COPD exacerbations in landmark trials (M2-124, M2-125, REACT). Most benefit seen in the chronic bronchitis with frequent exacerbator phenotype.<\/p>\n<h3>Will Rofaday make me lose weight?<\/h3>\n<p>Yes \u2014 average 2\u20133 kg in trials. Monitor weight at baseline and every 3 months. If loss exceeds 5%, review indication or stop.<\/p>\n<h3>Hur \u00e4r det med hum\u00f6rf\u00f6r\u00e4ndringar?<\/h3>\n<p>Rare but reported. Screen for depression at baseline; counsel patient and family to report new mood symptoms, anxiety, or suicidal thoughts. Stop and review.<\/p>\n<h3>Is Rofaday a bronchodilator?<\/h3>\n<p>No \u2014 it is anti-inflammatory only. Continue your LAMA, LABA, and (where indicated) ICS inhalers.<\/p>\n<h3>Can I take Rofaday during pregnancy?<\/h3>\n<p>Kontraindikerat.<\/p>\n<h3>How does Rofaday compare to triple therapy?<\/h3>\n<p>Triple inhaler (Triohale) and Rofaday tackle COPD exacerbations through different mechanisms (bronchodilation + inflammation suppression vs PDE4-mediated anti-inflammation). Some patients benefit from both.<\/p>\n<h3>What are the most important drug interactions?<\/h3>\n<p>Rifampicin (and other CYP3A4 inducers) reduce Rofaday levels by half \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0;border-radius:4px;font-size:13px;\"><strong>Medicinsk ansvarsfriskrivning:<\/strong> Denna sida \u00e4r utbildande och ers\u00e4tter inte professionell medicinsk r\u00e5dgivning. Konsultera alltid en kvalificerad v\u00e5rdgivare innan du b\u00f6rjar, slutar eller \u00e4ndrar n\u00e5gon inhalator eller respiratoriskt l\u00e4kemedel, s\u00e4rskilt om du har andra medicinska tillst\u00e5nd, tar andra receptbelagda l\u00e4kemedel, \u00e4r gravid eller ammar, eller \u00e4r \u00f6ver 65 \u00e5r.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterade alternativ<\/h3>\n<p>Andra produkter inom <strong>Kroniska tillst\u00e5nd<\/strong> som kunder \u00e4ven tittar p\u00e5:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/sv\/glycomet-gp\/\">Glycomet-GP<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/loratin\/\">Loratin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/decdan\/\">Decdan<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/sv\/hydrocl\/\">Hydrocl<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Reduces lung inflammation<br \/>\n\u2705 F\u00f6rb\u00e4ttrar lungfunktion<br \/>\n\u2705 Treats chronic bronchitis<br \/>\n\u2705 Decreases COPD exacerbations<br \/>\n\u2705 Enhances breathing capacity<\/p>\n<p>Rofaday contains Roflumilast.<\/p>","protected":false},"featured_media":60488,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3681,3141,3223],"product_tag":[4868,4869],"class_list":{"0":"post-60487","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-asthma-copd-treatment","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-rofaday","10":"product_tag-roflumilast","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product\/60487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/comments?post=60487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media\/60488"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media?parent=60487"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_brand?post=60487"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_cat?post=60487"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_tag?post=60487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}